Journal
MABS
Volume 5, Issue 5, Pages 655-659Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.25439
Keywords
autoantibody; EAE; FcRn; engineered antibodies; therapy
Categories
Funding
- National Multiple Sclerosis Society [RG 4308]
Ask authors/readers for more resources
Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently developed engineered antibodies that lower endogenous IgG levels by competing for binding to FcRn. These Abdegs (antibodies that enhance IgG degradation) can be used to directly assess the effect of decreased antibody levels in inflammatory diseases. In the current study, we show that Abdeg delivery ameliorates disease in an EAE model that is antibody dependent. Abdegs could therefore have promise as therapeutic agents for MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available